Consecutive patients with pneumonia, treated with cefepime (n = 66) or ceftazidime (n = 132), were evaluated in a retrospective, observational study. There was no significant difference between the two treatment groups with respect to age, underlying diseases, acute physical and chronic health evaluation score, intensive care unit admission, presence of sepsis, community or hospital acquisition, causative organism, duration of therapy, death, cure or improvement in infection, adverse events, superinfections, presence of vancomycin-resistant enterococcus (VRE) and resistance to therapy. Post-therapy hospitalization (days) and vancomycin co-administration were significantly lower, and time to vancomycin initiation significantly higher, in the cefepime compared with the ceftazidime group. The results suggest a trend towards less resistance on therapy, less VRE, reduced vancomycin use and shorter post-therapy hospitalization in patients treated with cefepime compared with ceftazidime. The clinical outcomes for hospitalized patients treated for serious pneumonia were similar between the two groups.
PinnerRWTeutschSMSimonsenLKlugLAGraberJMClarkeMJ: Trends in infectious diseases mortality in the United States. JAMA1996; 275: 189–193
2.
Centers for Disease Control and Prevention: Premature deaths, monthly mortality and monthly physician contacts — United States. MMWR Morb Mortal Wkly Rep1997; 46: 556
3.
FineMJSmithMACarsonCAMuthaSSSankeySSWeissfeldLA: Prognosis and outcomes of patients with community acquired pneumonia. JAMA1996; 275: 134–141
4.
FineMJAubleTEYealyDMHanusaBHWeissfeldLASingerDE: A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med1997; 336: 243–250
5.
KoivulaIStenMMakelaPH: Risk factors for pneumonia in the elderly. Am J Med1994; 96: 313–320
6.
PoeRHWahlGWQaziRKallayMCUtellMJMorrowGR: Predictors of mortality in the immunocompromised patients with pulmonary infiltrates. Arch Intern Med1986; 146: 1304–1308
7.
HedlundJUOrtqvistABKalinMScalia-TombaGGieseckeJ: Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet1992; 340: 396–397
8.
BassettiDCrucianiMSolbiatiMRubiniFGandolaLValentiG: Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections. Chemotherapy1991; 37: 371–375
9.
NiedermanMSBassJBCampbellGDFeinAMGrossmanRFMandellLA: Guidelines for the initial empiric therapy of community acquired pneumonia: proceedings of an American Thoracic Society Consensus Conference. Am Rev Resp Dis1993; 148: 1418–1426
10.
The British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med1993; 49: 346–350
11.
MandellLANiedermanMS: The Canadian Community Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community acquired pneumonia in adults: A conference report. Can J Infect Dis1993; 4: 25
12.
BartlettJGBreimanRFMandellLAFileTMJr: Community acquired pneumonia in adults: guidelines for management. Clin Infect Dis1998; 26: 811–838
13.
GarnerJSJarvisWREmoriTGHoranTCHughesJM: CDC definitions for nosocomial infections, 1988. Am J Infect Control1988; 16: 128–140
14.
Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol1995; 16: 105–113
15.
National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd edn.Approved Standards M7-A2. Villanova (PA): National Committee for Clinical Laboratory Standards1990
16.
FangGDFineMOrloffJArisumiDYuVLKapoorW: New and emerging etiologies for community-acquired pneumonia with implications for therapy; a prospective multicenter study of 359 cases. Medicine1990; 69: 307–316
MacDonaldKSScriverSRSkulnickMLowDE: Community acquired pneumonia: the future of the microbiology laboratory; focused diagnosis or syndromic management?Semin Respir Infect1994; 9: 180–188
19.
OrtqvistA: Initial investigation and treatment of the patient with severe community acquired pneumonia. Semin Respir Infect1994; 9: 166–179
20.
BartlettJGMundyL: Community acquired pneumonia. N Engl J Med1995; 333: 1618–1624
21.
TorresASerra-BatllesJFerrerAJimenezPCelisRCoboE: Severe community acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis1991; 144: 312–318
22.
MandellLA: Antibiotics for pneumonia therapy. Med Clin North Am1994; 78: 997–1014
23.
GleasonPPKapoorWNStoneRALaveJRObroskyDSSchulzR: Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community acquired pneumonia. JAMA1997; 278: 32–39
24.
MurrayPRWashingtonJAII: Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc1975; 50: 339–344
25.
WoodheadMAArrowsmithJChamberlain-WebberRWoodingSWilliamsI: The value of routine microbial investigation in community acquired pneumonia. Respir Med1991; 85: 313–317
26.
PachonJPradosMDCapoteFCuelloJAGarnachoJVeranoA: Severe community acquired pneumonia. Eetiology, prognosis, and treatment. Am Rev Respir Dis1990; 142: 369–373
27.
SorensenJForsbergPHakansonEMallerRSederholmCSorenL: A new diagnostic approach to the patient with severe pneumonia. Scand J Infect Dis1989; 21: 33–41
28.
GleckmanRDeVitaJHibertDPelletierCMartinR: Sputum gram stain assessment in community acquired bacteremic pneumonia. J Clin Microbiol1988; 26: 846–849
29.
FineMJOrloffJJRihsJDVickersRMKominosSKapoorWN: Evaluation of house staff physicians preparation and interpretation of sputum gram stains for community-acquired pneumonia. J Gen Intern Med1991; 6: 189–198
30.
Barrett-ConnorE: The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis1971; 103: 845–848
31.
ClynesNScullyBENeuHC: The use of cefepime (BMY 28142) to treat respiratory infections. Diagn Microbiol Infect Dis1989; 12: 257–260
32.
EdelsteinHChirurgiVOsterSKarpRCassanoKAikenS: A randomized trial of cefepime (BMY 28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother1991; 28: 569–575
33.
ZervosMJNelsonMand the Cefepime Study Group: Cefepime vs ceftriaxone for empiric treatment of hospitalized patients with community acquired pneumonia. Antimicrob Agents Chemother. 1998; 42: 729–733
34.
JonesRN: Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med1996; 100: 3–12
35.
KesslerREFung-TomeJ: Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5-year period. Am J Med1996; 100: 13–19
36.
McCabeRChirurgiVFarkasSAHaddowAGeinzGGreenS: A new therapeutic option for the treatment of pneumonia. Am J Med1996; 100: 60–67
37.
NeuHC: Safety of cefepime: A new extended-spectrum parenteral cephalosporin. Am J Med1996; 100: 68–75
38.
OsterSEdelsteinHCassanoKMcCabeR: Open trial of cefepime (BMY 28142) for infections in hospitalized patients. Antimicrob Agents Chemother1990; 34: 954–957
39.
SandersWEJrTenneyJHKesslerRE: Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis1996; 23: 454–461
40.
ThornsberryCBrownSDYeeYCBouchillonSKMarlerJKRichT: In vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother1993; 32: 31–53
41.
ThornsberryCYeeYC: Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States measured by two methods. Am J Med1996; 100: 26–38
42.
WashingtonJAJonesRNGerlachEHMurrayPRAllenSDKnappCC: Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime and cefuroxime. Antimicrob Agents Chemother1993; 37: 1696–1700
43.
YeeYCThornsberryCBrownSDBouchillonSKMarlerJKRichT: A comparative study of the in vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother1993; 32: 13–19
44.
PfallerMAJonesRNDoernGVKuglerKand The Sentry Participants Group: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother1998; 42: 1762–1770
45.
AufieroASturaniCZanonPMarruchellaAMichettiGNicolinE: Cefepime versus ceftazidime in the treatment of lower respiratory tract infections. J Chemother1997; 9: 213–218
46.
BarradellLBBrysonHM: Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs1994; 47: 471–505
47.
HoepelmanAlKieftHAounMKosmidisJStrandTVerhoefJ: International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother1993; 32 (Suppl B): 175–186
48.
LeophontePBertrandANouvetGMuirJFLuchtFDelavalP: A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother1993; 32 (Suppl B): 165–173
49.
Taibi-TronchePMassovaIVakulenkoSBLernerSAMobasheryS: Evidence for structural elasticity of class A β-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime. J Am Chem Soc1996; 118: 7441–7448
Fung-TomcJHuczkoEPearceMKesslerRE: Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime. Antimicrob Agents Chemother1988; 32: 1443–1445
52.
GradelskiEFung-TomcJHuczkoEKesslerRE: Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother1993; 32 (Suppl B): 75–80
53.
MarchouBMichea-HamzehpourMLucainCPechèreJC: Development of Beta-lactam resistant Enterobacter cloacae in mice. J Infect Dis1987; 156: 369–373
54.
PechèreJCVladoianuIR: Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother1992; 29: 563–573
55.
AmbrosePGRichersonMAStantonM-EBuiKNicolauDPNightingaleCH: Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infect Dis Clin Pract1999; 8: 245–251
56.
VergisENChowJWHaydenMKSnydmanDRZervosMJLindenPK: Interaction of virulence factors and antimicrobial therapy in patients with Enterococcus faecalis bacteremia; clinical and laboratory correlation for 125 patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO, 1998
57.
VergisENChowJWHaydenMKSnydmanDRZervosMJLindenPK: Vancomycin resistance predicts mortality in enterococcal bacteremia: A prospective, multicenter study of 375 patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, 1997
58.
MorrisJGShayDKHebdenJNMcCarterRJPerdueBEJarvisW: Enterococci resistant to multiple antimicrobial agents, including vancomycin. Ann Intern Med1995; 123: 250–259
